INVO Bioscience, Inc. (NASDAQ:INVO) Short Interest Up 146.4% in May

INVO Bioscience, Inc. (NASDAQ:INVOGet Free Report) was the target of a large growth in short interest in May. As of May 15th, there was short interest totalling 81,300 shares, a growth of 146.4% from the April 30th total of 33,000 shares. Currently, 2.2% of the company’s shares are sold short. Based on an average daily volume of 3,770,000 shares, the days-to-cover ratio is currently 0.0 days.

INVO Bioscience Price Performance

INVO stock traded up $0.01 during trading on Thursday, hitting $0.90. 23,126 shares of the stock traded hands, compared to its average volume of 2,365,396. INVO Bioscience has a 1 year low of $0.50 and a 1 year high of $8.60. The firm’s 50 day moving average is $1.01 and its two-hundred day moving average is $1.17. The company has a debt-to-equity ratio of 2.94, a quick ratio of 0.16 and a current ratio of 0.19.

Hedge Funds Weigh In On INVO Bioscience

A hedge fund recently bought a new stake in INVO Bioscience stock. Sabby Management LLC bought a new stake in INVO Bioscience, Inc. (NASDAQ:INVOFree Report) in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 231,023 shares of the company’s stock, valued at approximately $183,000. INVO Bioscience makes up about 0.1% of Sabby Management LLC’s investment portfolio, making the stock its 29th biggest holding. Sabby Management LLC owned 9.43% of INVO Bioscience at the end of the most recent quarter. Institutional investors own 12.02% of the company’s stock.

About INVO Bioscience

(Get Free Report)

INVO Bioscience, Inc, together with its subsidiary, a healthcare services fertility company, provides assisted reproductive technology solutions worldwide. It offers INVOcell, a medical device that allows fertilization and early embryo development to take place in vivo within the woman's body. The company was founded in 2007 and is based in Sarasota, Florida.

See Also

Receive News & Ratings for INVO Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for INVO Bioscience and related companies with's FREE daily email newsletter.